[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Taipei Veterans General Hospital, Taiwan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":686},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,50,82,108,128,156,181,224,254,277,300,332,357,379,409,436,466,496,518,543,563,586,610,637,660],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644942","atrial-remodeling-after-pfa-substrate-modification-for-persistent-af-peaf-100644942",false,"NCT07675395","Atrial Remodeling After PFA Substrate Modification for Persistent AF (PeAF)","Pulsed-Field Ablation for Persistent Atrial Fibrillation: Impact of Atrial Remodeling After Substrate Modification","Inclusion Criteria:\n\n* Diagnosis of persistent atrial fibrillation\n* Left atrial anteroposterior (AP) diameter greater than 4 cm and less than 6 cm\n* Anti-arrhythmic medications (except amiodarone) discontinued for at least 5 half-lives before the procedure\n* No use of beta-blockers or diuretics before or after the ablation procedure\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Paroxysmal atrial fibrillation\n* Previous left atrial surgery or catheter ablation procedure, including left atrial appendage closure\n* Atrial fibrillation due to reversible causes, such as thyroid disorders, acute alcohol intoxication, or other major surgeries within the 90 days preceding the procedure\n* Myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, or coronary artery bypass grafting within 90 days of the procedure\n* Known presence of cardiac thrombus\n* Stroke or transient ischemic attack within the last 90 days\n* Any other anatomical or comorbid condition that, in the investigator's opinion, could limit the patient's ability to participate in the clinical trial, comply with follow-up requirements, or impact the scientific validity of the clinical trial results","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Atrial fibrillation (AF) is associated with both electrical and structural remodeling of the left atrium. While successful catheter ablation has been shown to reverse some aspects of atrial remodeling, the impact of pulsed-field ablation (PFA) - a non-thermal ablation technology that selectively targets cardiomyocytes while sparing surrounding structures - on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unclear.\n\nThis is a prospective, single-center, single-arm observational study conducted at Taipei Veterans General Hospital. The study will enroll 30 patients with persistent atrial fibrillation who undergo pulmonary vein isolation (PVI) and extensive substrate modification using the FARAWAVE \u002F FARADRIVE Catheter and FARASTAR System.\n\nThe primary objective is to evaluate left atrial structural remodeling following PFA, including changes in LA size, atrial strain, extent of atrial fibrosis, and atrial hemodynamic function. The secondary objective is to assess AF-free survival between 3 and 12 months after the procedure, and its relationship to atrial remodeling. All participants will be followed for 12 months, with an interim analysis conducted once all subjects complete their 6-month follow-up.",[27,28,29,30],"Persistent Atrial Fibrillation","Atrial Fibrillation (AF)","Atrial Remodeling","Pulsed Field Ablation",[30,27,32,29,33,34,35,36],"Atrial Fibrillation","Substrate Modification","Atrial Fibrosis","Cardiac MRI","Posterior Wall Isolation","NOT_YET_RECRUITING","2026-06-30",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":21},"2026-07-01",{"date":45,"type":21},"2028-12-31",{"name":47,"class":48},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":49},"100642260","hypertonic-saline-inhalation-for-nontuberculous-mycobacterial-lung-disease-100642260","NCT07647575","Hypertonic Saline Inhalation for Nontuberculous Mycobacterial Lung Disease","A Randomized Controlled Trial of Early Versus Delayed Hypertonic Saline Inhalation in Treatment-Naïve Nontuberculous Mycobacterial Lung Disease","HiNTM","Inclusion Criteria:\n\n1. Adults aged 18 years or older.\n2. Diagnosis of nontuberculous mycobacterial lung disease (NTM-LD) according to ATS\u002FERS\u002FESCMID\u002FIDSA diagnostic criteria, including compatible clinical symptoms, radiographic findings, and microbiological evidence.\n3. Not receiving anti-NTM antibiotic treatment at the time of screening.\n4. Able and willing to provide written informed consent.\n5. Able to perform nebulized inhalation therapy using a mesh nebulizer at home.\n\nExclusion Criteria:\n\n1. Active tuberculosis.\n2. Human immunodeficiency virus (HIV) infection.\n3. Receiving active treatment for malignancy.\n4. Uncontrolled asthma.\n5. Frequent or clinically significant hemoptysis.\n6. History of intolerance, bronchospasm, or hypersensitivity during inhalation testing with hypertonic saline.\n7. Inability to prepare a mesh nebulizer or perform inhalation therapy at home.\n8. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study participation.",{"count":59,"type":21},262,[24],"This multicenter randomized controlled trial evaluates the clinical and microbiological effects of inhaled 3% hypertonic saline in treatment-naïve patients with nontuberculous mycobacterial lung disease (NTM-LD). Participants are randomized in a 1:1 ratio to either early initiation of 3% hypertonic saline for 6 months or delayed initiation consisting of normal saline inhalation during the first 3 months followed by 3% hypertonic saline during the subsequent 3 months.\n\nThe primary objective is to compare respiratory symptom improvement between hypertonic saline and normal saline at Month 3. Secondary objectives include evaluating sputum microbiological outcomes, radiographic changes, inflammatory markers, small airway function, treatment initiation, safety, and within-participant changes before and after switching from normal saline to hypertonic saline in the delayed-initiation arm.\n\nThe first participant was enrolled on October 3, 2025.",[63,64],"Nontuberculous Mycobacterial Lung Disease","Bronchiectasis",[66,67,63,64,68,69,70,71,72],"Hypertonic saline inhalation","Airway clearance therapy","Mycobacterium avium complex","Mycobacterium abscessus","Respiratory Severity Score","Nebulized Hypertonic Saline","NTM-LD","RECRUITING","2026-06-10",{"date":76,"type":41},"2026-06-15",{"date":78,"type":41},"2025-10-03",{"date":80,"type":21},"2028-07-31",{"name":47,"class":48},{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":49},"100634720","personalized-therapy-of-long-term-low-fodmap-in-ibs-treatment-role-of-mobile-application-and-microbiota-gut-brain-axis-100634720","NCT07543354","Personalized Therapy of Long-term Low FODMAP in IBS Treatment: Role of Mobile Application and \"Microbiota-gut-brain\" Axis","Inclusion Criteria:\n\n* Participants aged between 20 and 65 years.\n* Diagnosed with Irritable Bowel Syndrome (IBS)\n* Overall IBS symptoms remain unresolved or active at the time of enrollment.\n\nExclusion Criteria:\n\n* Inability to understand the study procedures or provide written informed consent.\n* Currently pregnant.\n* History of Inflammatory Bowel Disease (IBD).\n* Active infection within the past 90 days.\n* History of thyroid disease.\n* Major psychiatric disorders, including patients with significant anxiety or depression currently requiring treatment with anti-anxiety or anti-depressant medications.\n* History of epilepsy.\n* History of stroke, cerebral hemorrhage, or other central nervous system diseases.\n* Significant renal, hepatic, or major cardiovascular diseases.\n* Malignant diseases (cancer).\n* Type 2 diabetes.\n* Other chronic pain conditions.\n* History of abdominal surgery (excluding cholecystectomy or appendectomy) or any history of brain surgery.\n* Appendectomy or cholecystectomy performed within the past year.\n* Currently participating in other clinical trials.\n* Use of antibiotics or analgesics within 90 days prior to enrollment.\n* Newly initiated use of probiotics or prebiotics within 90 days prior to enrollment.\n* Current use of antipsychotic medications, antidiarrheal agents, probiotics, or analgesics.","20 Years","65 Years",{"count":91,"type":21},200,[24],"The purpose of this study is to evaluate the effectiveness of a mobile application (app) in helping clinicians and dietitians provide personalized low-FODMAP diet (LFD) therapy for patients with Irritable Bowel Syndrome (IBS). The study also aims to explore the potential biological mechanisms behind the clinical outcomes of this dietary intervention.\n\nParticipants diagnosed with IBS will be recruited and screened through clinical questionnaires. Eligible participants will receive dietary education from a dietitian and be randomly assigned to one of two groups: the AI-assisted LFDapp group or the LFD booklet group.\n\nThe study consists of three main phases:\n\nInitial Intervention (4-6 weeks): Participants will follow their assigned diet intervention and complete assessments regarding gastrointestinal symptoms, psychological traits (such as anxiety and depression), and quality of life.\n\nReintroduction Phase (12 weeks): Participants who respond well to the diet will enter a phase where specific foods are gradually reintroduced.\n\nPersonalization \\& Follow-up (4 weeks): A personalized diet will be established, followed by a final evaluation of bowel function and mental well-being.\n\nResearchers will use various standardized questionnaire to track changes in symptoms and overall well-being throughout the study period.",[95],"IBS - Irritable Bowel Syndrome",[97,98,99],"Low FODMAP","microbiota-gut-brain axis","IBS","2026-05-12",{"date":102,"type":41},"2026-05-15",{"date":104,"type":21},"2026-04",{"date":106,"type":21},"2029-06",{"name":47,"class":48},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":49},"100637522","explore-neural-mechanism-of-ocd-by-intervention-of-repetitive-transcranial-magnetic-stimulation-with-symptom-provocation-100637522","NCT07587112","Explore Neural Mechanism of OCD by Intervention of Repetitive Transcranial Magnetic Stimulation With Symptom Provocation","Inclusion Criteria:\n\n* Adults aged 18-65 years.\n* Diagnosis of obsessive-compulsive disorder according to DSM-5 criteria. Treatment resistance (i.e., inadequate response to pharmacological or non-pharmacological treatments) is not required.\n* Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥ 14, indicating at least mild to moderate symptom severity.\n\nExclusion Criteria:\n\n* Diagnosis of schizophrenia, organic psychotic disorder, bipolar disorder, alcohol use disorder, or substance use disorder.\n* High suicide risk within the past year.\n* Presence of significant medical or surgical conditions in an active phase.\n* History of, or planned, neurosurgical procedures, or presence of metallic implants in the brain or body (e.g., neurostimulators or cardiac pacemakers).\n* Structural brain abnormalities (e.g., brain tumor or arteriovenous malformation) or neurological disorders (e.g., meningitis, encephalitis, stroke, or epilepsy).\n* Pregnant women.\n* Inability to tolerate PET\u002FMRI examination due to claustrophobia or severe anxiety in confined spaces.\n* Any other conditions that may impair study compliance, including inability to cooperate, failure to provide informed consent, or other investigator-determined ineligibility after screening.\n* Use of medications that may increase seizure risk or suicide risk (e.g., certain antidepressants or antipsychotics).\n* Known allergy to 18F-FDG.\n* History of adverse reaction to TMS or allergy to the positioning cap.\n* Presence of metallic objects within approximately 30 cm of the cranial region (within the stimulation coil area).\n* Prior or current treatment with electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS).",{"count":115,"type":21},96,[24],"The purpose of this study is to investigate the differences in therapeutic efficacy of different deep TMS treatment coils and different brain stimulation targets on obsessive-compulsive symptoms, and to explore the neural mechanisms of obsessive-compulsive disorder using functional neuroimaging analysis.\n\n1. Inclusion Criteria:\n\n   Adults aged 18-65 years. Patients diagnosed with obsessive-compulsive disorder according to DSM-5 criteria.\n2. Study Design: Double-blind, randomized assignment.\n3. Number of Participants:\n\n   Sham group: 32 participants Active H7 group: 32 participants Active H1 group: 32 participants Total: 96 participants\n4. Study Procedures:\n\n   \\- Participant Screening and Baseline Assessment (Week 0) Determine eligibility for enrollment, including diagnostic confirmation, symptom assessment, screening for contraindications, and whether the participant has previously experienced adverse effects following TMS treatment. Participants with high suicide risk within the past year will be excluded.\n\n   Develop a personalized symptom provocation procedure for obsessive-compulsive symptoms (Carmi et al., 2018).\n\n   Complete baseline symptom severity assessments and brain positron emission tomography\u002Fmagnetic resonance imaging (PET\u002FMRI). Participants with structural brain abnormalities will be excluded.\n\n   Participants will be randomly assigned (1:1:1) into three groups, with a planned total enrollment of 96 participants.\n\n   Participants currently taking medication may continue their existing regimen, but no medication changes will be allowed during the study period.\n\n   \\- Treatment Phase (Week 1 to Week 6; duration: 6 weeks) Before each TMS session, participants will remove their shoes and socks, rest both hands flat on their thighs, keep their eyes looking straight ahead, and undergo measurement of resting motor threshold (RMT).\n\n   Approximately 3-5 minutes before each TMS session, trained personnel with ERP experience will assist participants in symptom provocation and record the participant's subjective level of distress.\n\n   The deep TMS treatment schedule consists of five sessions per week, one session per day, for six consecutive weeks. Adverse effects will be assessed and monitored at each session.\n\n   After completing the first treatment session, participants will be asked to guess which group they were assigned to, in order to evaluate the effect of treatment expectations on outcomes.\n\n   Symptom severity interviews will be conducted every two weeks.\n\n   \\- Post-treatment Assessment and Follow-up (Week 7 and after; duration: 2 weeks, then 6 months later) Within one week after completion of the deep TMS treatment course (within Week 7), participants will undergo follow-up brain PET\u002FMRI.\n\n   At the end of Week 8 (two weeks after treatment completion), symptom severity will be reassessed. Subsequent treatment plans will be discussed with participants, and outpatient follow-up will be arranged within six months.\n\n   Subsequent treatment options may include cognitive behavioral therapy, pharmacotherapy, and figure-8 rTMS.\n5. Statistical Analysis\n\n   * Expected Outcomes:\n\nThe H7 coil may improve obsessive-compulsive symptoms. Both the H7 and H1 coils may improve mood symptoms.\n\n\\- Descriptive and Inferential Statistics: Analysis of covariance (ANCOVA) will be used to compare differences among the three groups in MADRS, Y-BOCS, HAM-A, HDRS, and CGI-S scores.\n\nThe percentage of responders (% responders) will be calculated and compared among groups.\n\nRepeated-measures ANOVA will be used to examine within-group and between-group differences in symptom improvement before and after deep TMS treatment.\n\nPearson correlation analysis will be used to assess the association between symptom improvement and changes observed in PET\u002FMRI neuroimaging measures.\n\n\\- PET\u002FMRI Neuroimaging Analysis: Functional MRI analyses will include ROI-to-ROI functional connectivity and seed-based functional connectivity analyses.\n\nChanges in PET glucose uptake within specific regions of interest (ROIs) will also be examined to evaluate alterations in neural networks and brain function before and after deep TMS treatment.",[119],"Obsessive-Compulsive Disorder (OCD)","2026-05-08",{"date":122,"type":41},"2026-05-14",{"date":124,"type":41},"2025-09-22",{"date":126,"type":21},"2027-12-31",{"name":47,"class":48},{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":135,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":140,"studyType":141,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":155,"locationsCount":49},"100640415","fluorocholine-petmr-in-breast-cancer-100640415","NCT07587086","Fluorocholine PET\u002FMR in Breast Cancer","Use of Imaging Markers by Fluorocholine PET\u002FMR to Predict Molecular Subtypes and Clinical Outcomes of Breast Cancer: a Pilot Study","Inclusion Criteria:\n\n* Women aged 25-75 years old.\n* Women diagnosed as breast cancer by pathological diagnosis from core biopsy within 3 months and who will receive neoadjuvant chemotherapy (NAC) before surgery; or women with pathologically proven breast cancer within 3 months and who will receive operation (without pre-operative neoadjuvant chemotherapy).\n* Women whose ECOG between 0-2 points and life expectancy ≧ 3 months.\n\nExclusion Criteria:\n\n* Women who are unable to cooperate with the examinations\n* Women who are pregnant, lactating or are planning to be pregnant\n* Women with estimated GFR (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73m2 or acute renal failure within 3 months, past history of renal dialysis.\n* Past history of claustrophobia\n* Past history of anaphylactoid reactions to MRI contrast agents or PET tracer agents.\n* Women with cardiac pacemaker, aneurysmal clip, mechanical valve replacement, recently applied coronary artery stent (\\\u003C3 months).\n* Past history of breast cancer or other malignancy within 5 years.\n* Women who underwent chemotherapy within a year.\n* Women who are not suitable to join the study according to the assessment by investigators.","FEMALE","25 Years","75 Years",{"count":139,"type":21},195,"40 Weeks","OBSERVATIONAL","Objectives:\n\nOur study is conducted to use the pre-treatment FCH PET\u002FMR in breast cancer patients, to investigate whether the conventional PET\u002FMR imaging markers (SUVmax, MR spectroscopy-derived choline analysis, dynamic contrast-enhanced MRI, ADC analysis), and FCH\u002FMR radiomic features, deep learning (DL) analysis are associated with molecular subtypes, clinical outcomes, treatment response, survival, and which parameters are more accurate for prediction purposes.\n\nPrimary study purposes:\n\n-To investigate whether the pre-treatment FCH PET\u002FMR imaging parameters are associated with molecular subtypes of breast cancers, and to evaluate the diagnostic performance for prediction purpose.\n\nSecondary study purposes:\n\n\\- To investigate whether the pre-treatment FCH PET\u002FMR imaging parameters are associated with the factors related to clinical outcomes (histologic grade, prognosis) and to analyze which parameters are more accurate for prediction purposes.\n\nTest drug:\n\nName: 18F- Fluorocholine (18F-FCH) Dosage form: N-(\\[18F\\]fluoromethyl)-2-hydroxy-N,N-dimethylethan-1-aminium Strength: 3-5 MBq\u002Fkg per patient (5-6 mCi\u002FmL at time of injection (TOI)) Dosage and administration: Intravenous injection.\n\nSelection criteria:\n\n1. Women aged 25-75 years old.\n2. Women diagnosed as breast cancer by pathological diagnosis from core biopsy within 3 months and who will receive neoadjuvant chemotherapy (NAC) before surgery; or women with pathologically proven breast cancer within 3 months and who will receive operation (without pre-operative neoadjuvant chemotherapy).\n3. Women whose ECOG between 0-2 points and life expectancy ≧ 3 months.",[144,145],"Breast Neoplasms","Female",[147,148,149,150],"Breast Cancer","FCH(18F- Fluorocholine)","Radiomics","PET\u002FMRI",{"date":122,"type":41},{"date":153,"type":41},"2022-06-14",{"date":80,"type":21},{"name":47,"class":48},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":49},"100634718","transcranial-photobiomodulation-tpbm-for-somatic-symptoms-in-treatment-resistant-depression-100634718","NCT07543328","Transcranial Photobiomodulation (tPBM) for Somatic Symptoms in Treatment-Resistant Depression","The Clinical Efficacy of Prefrontal Transcranial Photobiomodulation (tPBM) in Patients With Treatment-Resistant Major Depressive Disorder: A Subgroup Analysis Focusing on Somatic Symptoms","Inclusion Criteria:\n\nMust have a current diagnosis of Major Depressive Disorder (MDD).\n\nThe clinical severity must be evaluated by a psychiatrist as moderate or above, defined as a Clinical Global Impression-Severity (CGI-S) score \\> 4 and a 17-item Hamilton Depression Rating Scale (HDRS-17) total score ≥ 18.\n\nMust be currently receiving stable antidepressant treatment for at least four weeks but showing inadequate response (treatment-resistant). This study will be conducted as an add-on therapy.\n\nMust have full behavioral capacity, normal intellectual functioning, and the ability to comprehend and sign the informed consent form.\n\nExclusion Criteria:\n\nIndividuals diagnosed with Bipolar Disorder or Schizophrenia.\n\nIndividuals with current or recent Substance Use Disorder.\n\nHistory of organic brain lesions (e.g., neurodegenerative diseases, epilepsy, stroke) or any medical conditions affecting central nervous system function.\n\nIndividuals with abnormal intellectual functioning based on clinical judgment (e.g., suspected intellectual disability, severe learning difficulties).\n\nIndividuals who are currently pregnant (due to limited evidence regarding the safety of tPBM during pregnancy).\n\nAny other condition that, in the investigator's judgment, would render the participant unable to cooperate, unsuitable for the study, or unwilling to sign the informed consent.",{"count":164,"type":21},40,[24],"The primary objective of this study is to evaluate the clinical efficacy of moderate-dose transcranial photobiomodulation (t-PBM) at different frequencies (10 Hz and 40 Hz) in patients with treatment-resistant depression (TRD). It further aims to explore the differential efficacy across various symptom subtypes, with a particular focus on the somatic symptom-dominant subtype. Additionally, this study will collect paired-pulse neurophysiological parameters (e.g., the ratio of cortical inhibition to excitation) to preliminarily explore the neural mechanisms underlying the modulation of cortical excitability by t-PBM intervention, and to analyze their correlation with the magnitude of clinical symptom improvement.\n\nThe specific aims of this study are as follows:\n\nTo evaluate the differential efficacy of t-PBM at varying frequencies (10 Hz vs. 40 Hz) in improving clinical depressive symptoms (as measured by scales such as HAM-D and MADRS).\n\nTo investigate the therapeutic response to t-PBM in patients with the somatic symptom-dominant depression subtype, analyzing its potential suitability for targeting specific symptoms.\n\nTo explore the changes in paired-pulse TMS parameters (e.g., SICI, ICF, and LICI) before and after t-PBM treatment, gaining preliminary insights into the potential association between its cortical modulatory effects and clinical outcomes.",[168,169],"Treatment-resistant Depression (TRD)","Major Depression Disorder",[171,169,172],"Photobiomodulation","tPBM","2026-04-24",{"date":175,"type":41},"2026-04-30",{"date":177,"type":41},"2026-01-06",{"date":179,"type":21},"2027-03-31",{"name":47,"class":48},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":187,"sex":17,"minAge":88,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":192,"conditions":193,"keywords":208,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},"100636162","develop-and-evaluate-an-artificial-intelligence-assisted-prehabilitation-program-for-returning-to-work-and-cost-effectiveness-analysis-in-patients-with-oral-cancer-100636162","NCT07562100","Develop and Evaluate An Artificial Intelligence Assisted Prehabilitation Program for Returning to Work and Cost-effectiveness Analysis in Patients With Oral Cancer","Inclusion Criteria:\n\n* Adult (\\> 20 years old and younger than 70 years old)\n* Newly diagnosed as OC and scheduled to receive cancer-related treatment\n* Able to use Mobile phone\n* Willing to sign an informed consent form after receiving a detailed explanation of the study's aims and procedures\n* Healthcare professionals involved in patients' care, including doctors, nurses, case managers, dietitians, rehabilitation therapists, and psychologists\n* Family members who are primary caregivers of the participating patients, engaged in different stages of medical care\n\nExclusion Criteria:\n\n* Risk populations for walking or performing exercise\n* Patients with cognitive impairment or psychiatric diseases",true,"70 Years",{"count":190,"type":21},650,[24],"The goal of this clinical trial is to develop and evaluate an Artificial Intelligence Assisted Prehabilitation Program (AI APP) for returning to work and cost-effectiveness analysis in patients with oral cancer (OC). The main questions it aims to answer are:\n\n* What kinds of needs are related to returning to work (RTW) in patients with OC from diagnosis to survival that we can incorporate into the development of AI APP to assist this population ?\n* How is the effect of the AI APP that based on findings from the first question for patients with OC on physical and psychological distress, fear of recurrence, self-efficacy in coping with cancer, communication, motor function, quality of life, and RTW?\n* How is the effect of the RTW AI prediction model to identify high-risk groups ? And how is the comprehensive cost effectiveness of benefits and quality of life of the AI APP for OC population?\n\nResearchers will compare patients without using AI APP to see if the AI APP works to assist with coping physical and psychological distress, communication, motor function, quality of life, and RTW issues for individuals with OC?\n\nParticipants will:\n\n* Be asked to fulfill a structural questionnaire, or engage in a semi-structured one-by-one interview or a focus group to assess their physical, psychological, and social support needs in the first stage.\n* Be invited to participant the pilot testing of AI APP in the second stage.\n* Be provided and trained by 3-month AI APP for 3 months or cared as usual in the third stage.\n* Complete a structural questionnaire and follow up one year, including the baseline (before using the AI app) and at 1-2 weeks, 3 months, 6 months, 9 months, and 12 months after the baseline.\n* Engage in one-by-one interview or a focus group to assess user experiences of the AI APP.",[194,195,196,197,198,199,200,201,202,203,204,205,206,207],"Oral Cancer","Psychological Distress","Communication Aids for Disabled","Physiotherapy","Return to Work","Prehabilitation","Physical Symptom Distress","Motor Function","Rehabilitation","Quality of Life","Cost Effectiveness","Artifical Intelligence","Prediction Model","Case Management, APP(Application)",[209,198,194,195,196,197,199,210,211,202,212,213,214,215],"Artificial Intelligence","Physical symptom distress","motor function","Quality of life","Cost effectiveness","prediction model","case management, APP(Application)",{"date":217,"type":41},"2026-05-01",{"date":219,"type":41},"2024-09-27",{"date":221,"type":21},"2029-12-01",{"name":47,"class":48},5,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":49},"100623755","statin-and-vitamin-d-treatment-in-patients-with-thyroid-eye-disease-100623755","NCT07400757","Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease","The Role of Statin and Vitamin D for the Treatment of Thyroid Eye Disease","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Diagnosis of active thyroid eye disease with a Clinical Activity Score (CAS) of 3 or higher\n* Low-density lipoprotein cholesterol (LDL-C) level of 100 mg\u002FdL or higher\n\nExclusion Criteria:\n\n* Prior orbital radiotherapy or orbital surgery for thyroid eye disease\n* Use of statins or high-dose vitamin D supplementation (greater than 400 IU per day) within 3 months prior to enrollment\n* Pregnancy\n* Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL\u002Fmin\u002F1.73 m²",{"count":232,"type":21},120,[24],"The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease. The study will also evaluate the safety of these treatments. The main questions it aims to answer are:\n\n* Does statin therapy change disease activity, as measured by changes in the Clinical Activity Score (CAS) and proptosis?\n* Does vitamin D supplementation change disease activity in patients with active thyroid eye disease?\n* Does combined treatment with statin and vitamin D produce different effects compared with either treatment alone or standard care?\n* What adverse events occur during treatment?\n\nResearchers will compare four groups: standard care alone, statin therapy plus standard care, vitamin D supplementation plus standard care, and combined statin and vitamin D therapy plus standard care.\n\nParticipants will:\n\n* Be randomly assigned to one of four treatment groups\n* Receive the assigned treatment for 24 weeks\n* Attend clinic visits for clinical assessments and blood tests at baseline and at 24 weeks\n* Be followed through medical record review for up to three years after completion of the intervention",[236,237],"Thyroid Eye Disease, TED","Graves Ophthalmopathy",[239,237,240,241,242,243,244,245,246,247],"Thyroid Eye Disease","Statin","Vitamin D","Atorvastatin","Autoimmune Disease","Inflammation","Randomized Controlled Trial","Factorial Design","Clinical Activity Score",{"date":175,"type":41},{"date":250,"type":41},"2026-02-24",{"date":252,"type":21},"2032-07-15",{"name":47,"class":48},{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":262,"studyType":141,"phases":4,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":49},"100551568","exploring-physical-and-psychological-needs-and-quality-of-life-in-patients-with-advanced-cancer-receiving-immunotherapy-100551568","NCT06461780","Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy","Exploring Physical and Psychological Distress, Financial Toxicity, Care Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy in One Year Follow-up: Psychometric Testing and Developing Prediction Models for Immune-related Adverse Events","Inclusion Criteria:\n\n* (1) Patients diagnose cancer and are informed\n* (2) Aged ≥18 years old\n* (3) Conscious clear and able to communicate",{"count":91,"type":21},"1 Year","During the immune checkpoint inhibitor therapy (ICIT), most of the patients stay at home, but there is lacking of the studies to explore their physical and psychological distress, financial toxicity, care needs, and quality of life. Therefore, the aims of this program are to (1) explore the immune-related adverse event (irAE) severity, distress, financial toxicity, and quality of life and examine the psychometric testing of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM); (2) establish the LINE group for assessing irAE severity and change trajectory of quality of life in one-year follow-up and (3) combined retrospective chart review and the finding in aim (2) to develop the risk prediction model in order to identify the high risk population.",[265,266,267,268,269,270,203],"Cancer","Immunotherapy","IrAE","Distress, Emotional","Care Need","Financial Toxicity",{"date":175,"type":41},{"date":273,"type":41},"2024-03-18",{"date":275,"type":21},"2028-08-01",{"name":47,"class":48},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":299,"locationsCount":49},"100501159","phase-2-intrathecal-pemetrexed-for-leptomeningeal-metastasis-in-egfr-mutant-nsclc-100501159","NCT05805631","Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC","Efficacy of Intrathecal Pemetrexed Combined With Tyrosine Kinase Inhibitor for Treating Leptomeningeal Metastasis in EGFR-Mutant NSCLC After Failure of Osimertinib","Inclusion criteria\n\n* At least 20 years of age.\n* Patients with metastatic non-squamous NSCLC harboring known EGFR activating mutation and with a diagnosis of probable or confirmed LM by the European Association of Neuro-Oncology-European Society for Medical Oncology (EANO-ESMO) guideline. \\[5\\] EGFR activating mutations include exon19 deletion, T790M, L858R, G719X, L861Q, or S768I.\n* Intracranial disease progression after osimertinib use, proved by contrast-enhanced MRI\n* Stable extra-cranial disease status, judged by investigators.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3 and a minimum life expectancy of 12 weeks\n* Normal bone marrow and organ function as defined below:\n\n  * Marrow: Hemoglobin ≥9gm\u002FdL, ANC ≥1500\u002Fmm3 platelets ≥100,000\u002Fmm3\n  * Hepatic: Serum total bilirubin ≤1.5 x upper limit of normal (ULN), ALT (SGPT) and AST (SGOT) ≤3 x ULN.\n  * Renal: Creatinine clearance (Ccr) ≥45 mL\u002Fmin.\n* For female patients of childbearing potential, agreement (by patient and\u002For partner) to use a highly effective form(s) of contraception that results in a low failure rate (\\\u003C 1% per year) when used consistently and correctly, and to continue its use for 5 months after the last dose of IP. Such methods include: combined (estrogen and progestogen containing) hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation together with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.\n* Ability to understand and willingness to sign an IRB approved written informed consent document.\n* Willing to provide CSF and plasma samples for ctDNA analysis.\n\nExclusion criteria\n\n* Uncontrolled extra-CNS disease which needs other systemic treatment than EGFR-TKI.\n* Uncontrolled tumor-related pain\n* Uncontrolled or symptomatic hypercalcemia (\\> 1.5 mmol\u002FL ionized calcium or Ca \\> 12 mg\u002FdL or corrected serum calcium \\> ULN). Patients who are receiving denosumab prior to study enrollment must be willing and eligible to receive a bisphosphonate instead while in the study.\n* Malignancies other than NSCLC within 5 years prior to study enrollment, with the exception of those with a negligible risk of metastasis or death (e.g., expected 5-year OS \\> 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous-cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent)\n* On chronic systemic steroid therapy more than 20 mg prednisolone per day (or equivalent) or on any other form of immunosuppressive medication\n* Has received a live-virus vaccination within 30 days of planned treatment start\n* Systemic cytotoxic chemotherapy or major surgery within 2 weeks of the first dose of study medication\n* Active infection requiring therapy\n* History of Human Immunodeficiency Virus (HIV) infection.\n* Hepatitis B carrier: Patients with HBV infection were required to be receiving effective antiviral therapy and have a viral load less than 100 IU\u002FmL at screening\n* Active Hepatitis C\n* Has received intrathecal chemotherapy within 2 weeks before the start of IP\n* Has received whole-brain radiotherapy (WBRT) within 2 weeks before the start of IP\n* Uncontrolled epilepsy\n* History of allergic reaction to intravenous pemetrexed.\n* Severe coagulation abnormality (INR \\> 2).\n* Severe symptomatic hydrocephalus that requires other treatment modalities other than IP\n* Bulky intra-cranial lesion that requires other treatment modalities other than IP",{"count":285,"type":21},23,[287],"PHASE2","Leptomeningeal metastasis (LM) is a complication of advanced non-small cell lung cancer (NSCLC). The incidence of LM in NSCLC patients is around 3-5 %, reaching 9.4 % of those with an epidermal growth factor receptor (EGFR) mutation. Generally, the efficacy of systemic treatment for LM is limited due to the blood-brain barrier. Osimertinib has a high central nervous system penetration rate, making it the preferred first-line treatment for EGFR-mutant NSCLC. Previous studies indicated that osimertinib had shown promising efficacy in pretreated patients harboring EGFR mutations and LM. However, intracranial disease progression eventually develops, and the prognosis of patients with LM progression after osimertinib is poor. Recently, intrathecal chemotherapy with pemetrexed (IP) was reported to be an alternative treatment in patients with NSCLC and LM. The results from a phase I\u002FII trial examining the efficacy and safety of IP in patients with EGFR-mutant NSCLC after the failure of previous TKI, and 83% of study enrollees received osimertinib before IP. The clinical response rate was 84.6%, and the median overall survival was 9.0 months. Despite initial promising efficacy, further trials are needed to verify these results. Therefore, the investigators plan to conduct a prospective study to examine the safety and effectiveness of IP combined with EGFR-TKI for patients with EGFR mutant NSCLC after osimertinib failure.",[290,291,292],"Carcinoma, Non-Small-Cell Lung","Epidermal Growth Factor Receptor","Leptomeningeal Metastasis","2026-03-23",{"date":295,"type":41},"2026-03-24",{"date":297,"type":41},"2024-08-01",{"date":126,"type":21},{"name":47,"class":48},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":307,"targetDuration":309,"studyType":141,"phases":4,"briefSummary":310,"conditions":311,"keywords":316,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":49},"100629362","feasibility-study-of-non-contact-imaging-based-physiological-monitoring-in-the-operating-room-100629362","NCT07473687","Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room","IBPM","Inclusion Criteria:\n\n1. Patients aged \\>18 years.\n2. Patients scheduled to undergo surgical procedures under general anesthesia.\n3. American Society of Anesthesiologists (ASA) Physical Status I, II, or III.\n\nExclusion Criteria:\n\n1. Patients aged \\\u003C 18 years.\n2. Pregnant patients.\n3. Patients whose facial images cannot be captured or recognized (e.g., due to surgical drapes, severe edema, or major trauma).\n4. Patients who refuse to participate or have not signed the informed consent form.\n5. Other cases deemed unsuitable for the study by the clinical physician or anesthesiologist.",{"count":308,"type":21},315,"1 Day","This study aims to evaluate the feasibility and accuracy of a non-contact, camera-based physiological monitoring technology in a perioperative setting (including anesthesia induction, surgery, and recovery).Conventional vital sign monitoring tools-such as ECG leads, blood pressure cuffs, and pulse oximeters-require direct skin contact, which may pose risks of cross-infection or skin injury in vulnerable populations (e.g., newborns or elderly patients). This research utilizes remote Photoplethysmography (rPPG) technology to estimate vital signs, including heart rate, blood pressure, and blood oxygen saturation (SpO2), by analyzing facial video captured via standard camera devices (Logitech C930, iPhone 16 Pro Max, and Samsung Galaxy S24 Ultra).The primary goal is to assess the consistency and stability of this non-contact system compared to clinical gold-standard monitors (Masimo Root, SedLine O3, and Radical-7) during actual surgical procedures. The findings will serve as a foundation for developing non-invasive, supplementary monitoring tools in dynamic clinical environments.",[312,313,314,315],"Cholecystitis","Liver Neoplasms","Cholelithiasis","Inguinal Hernia",[317,318,319,320,321,322,323],"General anesthesia","Intraoperative monitoring","Camera-based monitor","Non-contact Physiological Monitoring","Total Extraperitoneal Approach (TEP)","Remote Sensing","Perioperative Care","2026-03-10",{"date":326,"type":41},"2026-03-16",{"date":328,"type":41},"2026-01-08",{"date":330,"type":21},"2030-06-30",{"name":47,"class":48},{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":348,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":354,"leadSponsor":356,"locationsCount":4},"100628577","effectiveness-of-chatbot-for-improving-caregiving-outcomes-in-primary-caregivers-of-geriatric-pneumonia-patients-a-study-on-knowledge-attitude-and-practice-100628577","NCT07463443","Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Study on Knowledge, Attitude and Practice.","Inclusion Criteria:\n\n* (1)Patients with a primary diagnosis of pneumonia during the current hospitalization.(2)Patients aged 65 years or older.(3)Primary caregivers aged 18 years or older.(4)Primary caregivers who can read and understand Mandarin Chinese.(5)Primary caregivers who own a mobile device (e.g., smartphone or tablet) and can use the chatbot application.\n\nExclusion Criteria:\n\n* (1)Primary caregivers who do not live with the patient.(2)Primary caregivers who have received formal training as professional nursing assistants or caregivers.(3)Primary caregivers who are currently or were formerly healthcare professionals (e.g., physicians, nurses, therapists).(4)Primary caregivers who do not possess a mobile device or are unable to use chatbot applications.",{"count":339,"type":21},150,[24],"Pneumonia is a leading cause of death and hospitalization among the elderly in Taiwan. High-quality home care is essential to recovery and reducing readmission, yet primary caregivers often lack the specific skills needed, such as airway clearance and safe feeding techniques. Traditional education, consisting of one-time verbal instructions and paper brochures, often lacks interactivity and real-time support.\n\nThis study introduces \"Pneumonia Care Helper,\" an interactive LINE chatbot designed to provide digital health education. The goal is to evaluate whether this digital tool is more effective than traditional paper-based education in improving the knowledge, attitudes, and caregiving practices of primary caregivers of elderly pneumonia patients. The study will compare the outcomes of caregivers using the chatbot versus those receiving standard paper-based instructions over a 5-day intervention period.",[343,344,345,346,347],"Pneumonia","Family Caregivers","Knowledge, Attitudes, Practice","Chatbot","Geriatric Patient",[343,344,345,346,349],"Geriatric patient","2026-03-05",{"date":352,"type":41},"2026-03-11",{"date":324,"type":21},{"date":355,"type":21},"2027-02-24",{"name":47,"class":48},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":365,"briefSummary":366,"conditions":367,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":378},"100506552","effects-of-bright-light-exposure-combined-with-specific-exercise-training-best-program-in-patients-with-cancer-100506552","NCT05875870","Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer","Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program on Sleep-Wake Rhythm, Physical and Psychological Symptoms, and Quality of Life of Patients With Thoracic Cancer: A Series Study.","Inclusion Criteria:\n\n1. Patients with newly diagnosed primary lung cancer or esophageal cancer, from the first stage to the third stage.\n2. At least 20 years of age.\n3. Able to communicate in Mandarin Chinese or Taiwanese.\n4. Literate and free from cognitive disabilities.\n5. The attending physician agrees to participate in the study.\n6. Those who can connect to the Internet with mobile devices such as computers, mobile phones, and tablets, or those whose family members can assist in the operation.\n7. Those with Karnofsky Performance Scale (KPS) greater than or equal to 70 points.\n8. Those who are hospitalized for lung cancer or esophageal cancer lesion resection.\n\nExclusion Criteria:\n\n1. Congestive heart failure.\n2. Orthopedic diseases of the lower extremities that limit one's walking ability.",{"count":91,"type":21},[24],"This study plans to investigate the effectiveness of six-week light exposure combined with an exercise training program on improving sleep-wake rhythm, physical and mental symptoms, quality of life, one-year recurrence rate, and one-year survival rate of patients with lung and esophageal cancer.",[368,369],"Lung Neoplasm","Esophageal Neoplasms","2026-02-13",{"date":372,"type":41},"2026-02-17",{"date":374,"type":41},"2023-07-24",{"date":376,"type":21},"2028-05-15",{"name":47,"class":48},2,{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":187,"sex":17,"minAge":88,"maxAge":89,"enrollmentInfo":386,"targetDuration":4,"studyType":22,"phases":388,"briefSummary":390,"conditions":391,"keywords":396,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":49},"100606768","phase-1-safety-and-feasibility-of-temporal-interference-brain-stimulation-for-treatment-in-psychiatric-disorders-100606768","NCT07179848","Safety and Feasibility of Temporal Interference Brain Stimulation for Treatment in Psychiatric Disorders","Phase I Clinical Trial of a New Non-invasive Deep Brain Stimulation Technique","Inclusion Criteria:\n\n* Healthy adults from the community\n* Age between 20 and 65 years old\n* No diagnosis of severe psychiatric disorders\n* No family history of psychiatric diseases\n\nExclusion Criteria:\n\n* Age below 20 years old or above 65 years old\n* Currently prescribed any medication\n* Diagnosis of psychiatric disorders (e.g., Major Depressive Disorder, Bipolar Disorder, Schizophrenia)\n* Diagnosis of neurological disorders (e.g., Dementia, Stroke, Parkinson's disease)\n* History of substance abuse\n* Diagnosis of cancer or malignant tumors\n* Chronic kidney failure or undergoing hemodialysis\n* Pregnant or breastfeeding\n* Severe arrythmia, presence of pacemaker, or metal implants in the brain\n* Claustrophobia\n* History or family history of seizure\n* History of syncope\n* Organic brian disease, brian trauma, or history of neurosurgery\n* Received electroconvulsive therapy or repetitive transcranial magnetic stimulation within the past month\n* Skin disorders (e.g., dermatitis, psoriasis, eczema)\n* Currently participating in other clinical interventional trials\n* Presence of any metal implants or devices affected by electromagnetic fields",{"count":387,"type":21},80,[389],"PHASE1","The goal of this clinical trial is to validate if temporal interference brain stimulation (TIBS) is safe in healthy volunteers aged 20 to 65. The main questions it aims to answer are:\n\n* Is it safe to apply TIBS intervention to the left hippocampus in healthy participants?\n* Is it safe to apply TIBS intervention to the left insula in healthy participants?\n* Is it safe to apply TIBS intervention to the left anterior cingulate cortex in healthy participants?\n* Is it safe to apply TIBS intervention to the right inferior frontal cortex in healthy participants?\n\nParticipants will:\n\n* Be Randomly allocated to either sham-first group or treat first-group, stratified by stimulated brain region, following a crossover-controlled experimental design\n* Complete baseline cognitive evaluations and mental status assessments, and undergo a baseline MRI scan on the same day\n* Receive stimulation for 5 consecutive days, followed by a 2-days washout period, then complete the remaining 5 days of stimulation.\n* Complete post-intervention cognitive evaluations and mental status assessments, and undergo a post-intervention MRI scan on the same day",[392,393,394,395],"Health Adults","Temporal Interference Stimulation","Safety and Effectiveness","Crossover Study",[397,393,398,399,400],"Hippocampus","Insula","Anterior Cingulate Cortex","Inferior Frontal Cortex","2026-02-05",{"date":403,"type":41},"2026-02-09",{"date":405,"type":41},"2025-02-26",{"date":407,"type":21},"2026-10",{"name":47,"class":48},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":135,"minAge":89,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":426,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":49},"100620786","exploring-the-effects-of-hand-and-foot-exercise-intervention-in-older-adults-with-gynecological-cancer-receiving-chemotherapy-improvement-of-peripheral-neuropathy-and-quality-of-life-100620786","NCT07362147","Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life","Inclusion Criteria:\n\nIndividuals aged 65 or older diagnosed with gynecological cancer (stage II to IV) by a physician, without skin or nail lesions.\n\nIndividuals who have received at least one course of chemotherapy within the past year and have peripheral neuropathy, with chemotherapy drugs including paclitaxel (Paclitaxel or Docetaxel) or platinum-based drugs (Cisplatin or Carboplatin), and may receive combined targeted or immunotherapy.\n\nIndividuals who are conscious and able to communicate in Mandarin, Taiwanese, or written language.\n\nExclusion Criteria:\n\nSkin or nail lesions. Edema of 3+ or more in the extremities. History of diagnosis of diabetes, neuropathy, peripheral arterial ischemia, or multiple organ failure.\n\nDistal bone or skin metastases. Patients who have interrupted chemotherapy. Patients who have participated in similar studies.",{"count":416,"type":21},74,[24],"Paclitaxel-based drugs are commonly used adjuvant chemotherapy for gynecological cancer patients. Peripheral neuropathy, a side effect of this treatment, presents with symptoms such as numbness, tingling, decreased skin and reflex sensation, and impaired function in the hands and feet, thus affecting quality of life. Peripheral neuropathy is a side effect caused by the neurotoxicity of certain chemotherapeutic drugs, including paclitaxel and platinum-based drugs, resulting from the cumulative toxicity of specific drug doses. While numerous international studies have confirmed the preventative effects of hand and foot movement interventions, there is a lack of relevant literature in China. Therefore, this study aims to explore the effects of hand and foot movement interventions on elderly gynecological cancer patients undergoing chemotherapy.",[420,421,422,423,424,425],"Peripheral Neuropathy","Cervical Cancer","Endometrial Cancer","Ovarian Cancer","Vaginal Cancers","Fallopian Tube Cancers",[427],"hand and foot exercises, chemotherapy, gynecological cancer, peripheral neuropathy, quality of life","2026-01-21",{"date":430,"type":41},"2026-01-23",{"date":432,"type":21},"2026-01-01",{"date":434,"type":21},"2027-11-30",{"name":47,"class":48},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":446,"briefSummary":447,"conditions":448,"keywords":453,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":49},"100619406","guard-ph-guided-use-of-ai-ecg-for-risk-detection-of-ph-in-surgery-guard-ph-trial-100619406","NCT07344207","GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial)","A Prospective, Open-Label, Randomized Controlled Trial of an Artificial Intelligence Enabled Electrocardiography System for Preoperative Detection of Pulmonary Hypertension and Related Diseases(GUARD-PH)","GUARD-PH","Inclusion Criteria:\n\n1. Age between 18 and 80 years.\n2. Patients scheduled for non-cardiac surgery under general anesthesia.\n3. Patients who have a scheduled standard preoperative electrocardiogram (ECG).\n4. Patients capable of understanding the study and willing to provide medical records for research purposes, and who have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients scheduled for emergency surgery.\n2. Patients who explicitly refuse to participate or withdraw consent.\n3. Patients with specific comorbidities that interfere with ECG interpretation or data collection (e.g., implanted pacemakers).",{"count":445,"type":21},1380,[24],"This study is a prospective, open-label, randomized controlled trial designed to evaluate a new artificial intelligence (AI) tool for heart monitoring. Researchers will use an AI-enabled electrocardiography (ECG) system to screen patients before they undergo surgery. The main goal is to determine if this AI system can accurately detect pulmonary hypertension and related heart diseases in the preoperative setting. The study is being conducted at Taipei Veterans General Hospital.",[449,450,451,452],"Pulmonary Hypertension (Diagnosis)","Pre-operative Assessment","Postoperative Complications (Cardiopulmonary)","Treatment Outcomes",[209,454,455,456,457],"Electrocardiography","AI-ECG","Preoperative Detection","Screening","2026-01-07",{"date":460,"type":41},"2026-01-15",{"date":462,"type":21},"2026-01-05",{"date":464,"type":21},"2027-01-05",{"name":47,"class":48},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":49},"100616441","the-effectiveness-of-an-innovative-inhalation-training-device-in-improving-medication-accuracy-dyspnea-and-quality-of-life-in-elderly-patients-with-chronic-obstructive-pulmonary-disease-100616441","NCT07305649","The Effectiveness of an Innovative Inhalation Training Device in Improving Medication Accuracy, Dyspnea, and Quality of Life in Elderly Patients With Chronic Obstructive Pulmonary Disease","pMDII","Inclusion Criteria:\n\n* Age ≥ 65 years old\n* Clinically diagnosed with Chronic Obstructive Pulmonary Disease (COPD) according to GOLD criteria\n* Currently using pressurized Metered Dose Inhaler (pMDI) medications\n* Ability to communicate and understand instructions in Mandarin or Taiwanese\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Diagnosis of severe cognitive impairment (e.g., dementia) that may interfere with participation\n* Acute COPD exacerbation requiring hospitalization within the past 30 days\n* Concurrent enrollment in another interventional clinical trial\n* Severe visual or hearing impairment that may limit the ability to follow inhaler training instructions\n* Other diagnosed pulmonary diseases (e.g., lung cancer, pulmonary fibrosis) that may affect the assessment of COPD outcomes",{"count":474,"type":21},82,[24],"This study aims to evaluate the effectiveness of an innovative inhaler training device, \"Golden Rhino\" (pMDI Practice Tool), in improving inhalation technique accuracy, dyspnea severity, and quality of life among elderly patients with chronic obstructive pulmonary disease (COPD). The device integrates a weighted valve and musical cues to guide patients in synchronizing their breath with proper pMDI inhalation technique. Participants will be randomly assigned to either standard nursing guidance or nursing guidance plus device-based training. Outcome measures include pMDI usage accuracy, dyspnea severity, and EQ-5D quality of life scores at baseline and follow-up.",[478],"Chronic Obstructive Pulmonary Disease",[480,481,482,483,484,212,485,486,487,488],"COPD","Inhaler training","pMDI","Elderly patients","Dyspnea","EQ-5D","CAT","mMRC","Inhaler technique","2025-12-12",{"date":491,"type":41},"2025-12-26",{"date":493,"type":21},"2025-12-19",{"date":45,"type":21},{"name":47,"class":48},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":187,"sex":17,"minAge":503,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":49},"100614512","evaluation-of-ai-assisted-ldct-screening-in-lung-cancer-100614512","NCT07280559","Evaluation of AI-assisted LDCT Screening in Lung Cancer","Evaluation of AI Medical Software-assisted LDCT Interpretation in Lung Cancer Screening and Prognosis: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Family History of Lung Cancer: Males aged 45-74 or females aged 40-74 with first-degree relatives (parents, siblings, or children) diagnosed with lung cancer.\n2. Heavy Smoking History: Ages 50-74 with ≥20 pack-years smoking history, currently smoking or quit \\\u003C15 years ago.\n3. General Screening Participants: Adults aged 40 years or older attending routine health check-ups.\n\nExclusion Criteria:\n\n1. Pregnant women.\n2. Chest CT or other higher-radiation chest imaging within the past 12 months.\n3. Individuals holding a major illness certificate for lung cancer.\n4. Inability to undergo thoracic puncture or surgery.\n5. Inability to hold breath or otherwise complete the scanning procedure.\n6. Hemoptysis of unknown cause within the past month.\n7. Chest X-ray within the past month showing suspicious lung lesions.\n8. Unexplained weight loss \\>6 kg within the past year.\n9. History of lung cancer within the past three years.\n10. Presence of other severe diseases with an expected life expectancy \\\u003C5 years.","40 Years","74 Years",{"count":506,"type":21},1120,[24],"This multicenter pragmatic randomized controlled trial evaluates whether AI-assisted interpretation of low-dose CT (LDCT) improves lung cancer screening performance compared with standard reading. Eligible participants are randomized to AI-assisted or conventional interpretation. The study assesses diagnostic accuracy, efficiency, lung cancer incidence, mortality, recurrence, and smoking cessation outcomes. Results will inform the clinical utility and potential implementation of AI-assisted LDCT in routine screening practice.",[510],"Lung Cancer","2025-12-09",{"date":489,"type":41},{"date":514,"type":21},"2025-12-11",{"date":516,"type":21},"2031-12-31",{"name":47,"class":48},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":526,"conditions":527,"keywords":531,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":537,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":49},"100614511","analysis-of-breath-sounds-during-surgery-100614511","NCT07280546","Analysis of Breath Sounds During Surgery","BREATHSOUND","Inclusion Criteria:\n\n* Age ≥ 20 years\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Scheduled for elective surgery under general anesthesia\n* Provided written informed consent\n\nExclusion Criteria:\n\n* History of respiratory disease (e.g., COPD, severe asthma)\n* Previous airway surgery or anatomical abnormalities that interfere with breath sound assessment\n* Refusal to participate or inability to comply with study procedures",{"count":20,"type":21},"This study aims to analyze breath sounds during surgery by using electronic stethoscope sensors attached to patients under general anesthesia. The study will evaluate whether breath sound monitoring can provide useful information for respiratory management, assist anesthesiologists in early detection of abnormal breathing events, and support safer perioperative care. A total of 30 adult patients undergoing elective surgery under general anesthesia will be enrolled.",[528,529,530],"General Anesthesia","Intraoperative Monitoring","Respiratory Sounds",[532,533,534,535,536],"Breath sounds","Perioperative care","Airway monitoring","Respiratory complications","Double-lumen endotracheal tube (DLT)",{"date":489,"type":41},{"date":539,"type":41},"2025-09-03",{"date":541,"type":21},"2026-09-30",{"name":47,"class":48},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":22,"phases":551,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":562},"100603440","phase-1-a-phase-iii-trial-of-hcb101-in-combination-with-pembrolizumab-for-patients-with-platinum-refractory-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-sirhn-trial-100603440","NCT07136545","A Phase I\u002FII Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)","* Inclusion Criteria\n\n  * 1\\. Subjects are able to understand and willing to provide signed informed consent as described in protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, including study visits and study-related procedures.\n  * 2\\. Male and female subjects of ≥18 years of age, inclusive, at the time of signing the informed consent.\n  * 3\\. With histologically\u002Fcytologically confirmed diagnosis of HNSCC\n  * 4\\. With progression after 1st cisplatin based therapy for R\u002FM HNSCC or within 6 months after cisplatin based CCRT\n  * 5\\. Must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n  * 6\\. Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at Screening.\n  * 7\\. Have a life expectancy of ≥12 weeks (according to the Investigator's judgment).\n  * 8\\. Have adequate organ function, as indicated by the following laboratory parameters in below (had not received a blood transfusion, apheresis infusion, erythropoietin, granulocyte colony-stimulating factor, and other relevant medical support within 14 days prior to the administration of the first dose of study intervention).\n\n    * a) Absolute neutrophil count ≥1.5 × 109\u002FL\n    * b) Platelets ≥75 × 109\u002FL\n    * c) Hemoglobin ≥9.5 g\u002FdL\n    * d) Total bilirubin ≤1.5 × upper limit of normal (ULN), \\\u003C3.0 × ULN if known Gilbert's disease\n    * e) Alanine aminotransferase and aspartate aminotransferase ≤3× ULN and ≤5× ULN for subject with liver metastasis\n    * f) Creatinine clearance ≥50 mL\u002Fmin (using Cockcroft Gault equation)\n    * g) Coagulation: International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5× ULN (The INR applies only to subjects who do not receive therapeutic anticoagulation). For subjects receiving therapeutic anticoagulation, the INR should be within the therapeutic range for the intended use of the anticoagulants.)\n  * 9\\. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test during the Screening Period (within 7 days prior to the first dose of the study intervention).\n* Exclusion Criteria\n\n  * 1\\. Medical Conditions:\n\n    * a) With a known history of hypersensitivity to any components of the study intervention.\n    * b) Subjects who have other malignancies requiring treatment within 2 years prior to the first dose of study intervention will be excluded, except for radically treated locally curable basal or squamous cell skin cancer and other malignancies that have been treated with no relapse within 2 years.\n    * c) Primary tumor in the central nervous system (CNS), or active or untreated CNS metastases and\u002For carcinomatous meningitis. Subjects with previously treated brain metastases may participate, provided they are clinically stable for at least 28 days and have no evidence of new or enlarging brain metastases and no requirements for high-dose corticosteroids 14 days prior to dosing with study intervention. Subjects on low-dose corticosteroids (\\\u003C20 mg prednisolone or equivalent per day) may participate.\n    * d) Clinically significant cardiovascular condition, including 1)History of congestive heart failure (New York Heart Association Class \\>2), with only heart failure with preserved ejection fraction (HFpEF) included; 2)History of unstable angina within 6 months prior to the first dose of study intervention; 3)New-onset angina or myocardial infarction within 6 months prior to the first dose of study intervention; 4)New-onset of atrial fibrillation, supraventricular arrhythmia, or ventricular arrhythmia within 6 months prior to the first dose of study intervention and still in unstable condition and requiring treatment or intervention. History of atrial fibrillation, supraventricular arrhythmia, or ventricular arrhythmia will be allowed, provided the condition is stably controlled.\n    * e) History or presence of an abnormal ECG that, in the Investigator's opinion, is clinically meaningful (including QT interval corrected for heart rate using Fridericia's correction \\[QTcF\\] \\>470 msec at Screening, pacemaker installation, or previous diagnosis of congenital long QT syndrome).\n    * f) Any previous treatment-related toxicities which have not recovered to ≤ Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia (Note: subjects with chronic Grade 2 toxicities which are well managed and stable may be eligible per the discretion of the Investigator, Grade 2 chemotherapy-induced neuropathy.)\n    * g) With known inherited or acquired bleeding disorders or bleeding diathesis.\n    * h) With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months.\n    * i) With active autoimmune diseases that required systemic treatment (e.g., disease-modifying agents, corticosteroids, or immunosuppressants) within the past two years are excluded. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroids for adrenal or pituitary insufficiency) is allowed.\n    * j) With a history of or current non-infectious pneumonitis.\n    * k) With a history of severe hypersensitivity to monoclonal antibodies.\n  * 2\\. Prior\u002FConcomitant Therapy\u002FTreatment\n\n    * a) Subjects who have undergone major surgery or radical radiotherapy within 28 days prior to the first dose of study intervention.\n    * b) Subjects who have undergone any investigational or approved systemic cancer therapy (including chemotherapy, immunotherapy, hormonal therapy, and herbal\u002Falternative therapies with anti-cancer indications or targeted therapy) within 14 days or 5 half lives, whichever is longer, prior to the first dose of the study intervention.\n    * c) Subjects who have used herbal medication within 14 days prior to the first dose of the study intervention.\n    * d) Subjects who are active using of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on a case-by-case basis. There will be no restriction for daily aspirin ≤ 100 mg\u002FQD.\n    * e) Subjects who have received any treatment targeting the CD47 or SIRPα pathway.\n    * f) Subjects who have previously received pembrolizumab treatment.\n    * g) Subjects who have received a live vaccine within 30 days prior to pembrolizumab administration.\n    * h) Subjects diagnosed with immunodeficiency, receiving systemic steroid therapy, or having received any other form of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab.\n  * 3\\. Participation in another clinical study with an investigational product administered in the last 14 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study intervention. An investigational device was used within 28 days prior to the first dose of study intervention.\n  * 4\\. Reproductive and breastfeeding\n\n    * a) Women of reproductive potential who are unable to use effective contraception during treatment and for 4 months after the last dose.\n    * b) Women who are breastfeeding during treatment and for 4 months after the last dose.\n  * 5\\. Infections:\n\n    * a) An uncontrolled acute infection, an active infection requiring systemic treatment, or subjects who have received systemic antibiotics within 7 days prior to the first dose of the study intervention (Note: prophylaxis use of systemic antibiotics treatment for upper tract infection is allowed as long as there is no violation of the requirement of concomitant medications).\n    * b) Known history of human immunodeficiency virus (HIV) infection.\n    * c) Active tuberculosis.\n    * d) Known history of hepatitis B or hepatitis C infection. Subjects who test positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody.\n  * 6\\. Any other medical (e.g., Child-Pugh class B or C, pulmonary, metabolic, congenital, endocrinal or CNS disease, etc.), psychiatric, or social condition deemed by the Investigator to be likely to interfere with a subject's rights, safety, welfare or ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.",{"count":550,"type":21},50,[389,287],"This is a non-randomized, open-label, dose-escalation and dose-expansion phase I\u002FII clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with pembrolizumab in patients with platinum-refractory recurrent\u002Fmetastatic HNSCC. The trial consists of two phases: the dose-escalation phase (I) and the dose-expansion phase (II).\n\nSubjects will receive a weekly single dose of HCB101 IV infusion over 60 (±10) minutes on Days 1, 8, and 15 in each 21-day cycle in combination with pembrolizumab (200 mg IV day 1; given every 21 days) until unacceptable AE(s), radiographic or clinically documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study whichever occurs first.",[554],"HNSCC",{"date":556,"type":41},"2025-09-10",{"date":558,"type":41},"2025-08-01",{"date":560,"type":21},"2026-12-31",{"name":47,"class":48},3,{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":585,"locationsCount":49},"100538565","focused-ultrasound-for-drug-resistant-epilepsy-100538565","NCT06292494","Focused Ultrasound for Drug-resistant Epilepsy","Inclusion Criteria:\n\n* Patients aged 20 and above.\n* Localized refractory epilepsy (ineffective with maximum doses of two or more anti-seizure medications).\n* Seizure frequency records for at least one month prior to the trial.\n* Patients who have undergone a complete preoperative examination, including EEG, MRI, and positron emission tomography (PET).\n* Capable of undergoing high-resolution computed tomography (CT scan), and SDR (Skull Density Ratio) ≥ 0.3.\n* Must have a body type suitable for entry into the magnetic resonance imaging (MRI) machine and be able to tolerate MRI scans.\n* During the surgical procedure, communication with the physician and the expression of sensory perceptions are essential; general anesthesia is not required.\n* Must be able to voluntarily press the stop button.\n* Willing to undergo removal of hair from the treatment site.\n\nExclusion Criteria:\n\n* This product is not suitable for individuals with contraindications related to MRI, such as those with metallic implants, those unable to undergo MRI, severe claustrophobia, or those with adverse reactions to contrast agents.\n* Individuals with implants in the brain or skull, such as shunts, electrodes, hard brain membrane patches, or electrode plates, that cannot be avoided along the expected path of brain ultrasound.\n* Patients along the expected path of brain ultrasound who cannot avoid structures or sensitive tissues with energy absorption (e.g., previous brain shunt surgery sites, surgical metal clips, or any hard implants).\n* Patients with extensive scabbing along the expected path of brain ultrasound.\n* Patients who have used contrast agents (e.g., MRI, ultrasound) within the past 24 hours before treatment.\n* Patients with other high-risk brain disorders (e.g., intracranial aneurysm).\n* Patients with intraoperative or postoperative bleeding risk:\n\n  1. Those with a history of cerebrovascular disease (multiple strokes or strokes within the past six months) or a history of cerebral hemorrhage and stroke.\n  2. Those with abnormal bleeding, intracranial bleeding, coagulation disorders, or a history of bleeding or clotting disorders, either during or after surgery.\n* Patients taking or injecting anticoagulant medications such as aspirin, coumadin, heparin, novel oral anticoagulants (NOACs), etc., which may lead to prolonged bleeding. Medication should be discontinued for 3-7 days before treatment.\n* Patients with severe uncontrolled hypertension (systolic blood pressure \\> 180 mmHg after stable medication, diastolic blood pressure \\> 100 mmHg).\n* Patients unable to communicate with the physician during the treatment process.\n* Unstable cardiac conditions (heart rate \\> 180 beats\u002Fminute or \\\u003C 40 beats\u002Fminute; systolic blood pressure \\> 180 mmHg or \\\u003C 90 mmHg).\n* Substance abuse (use of illegal drugs or using medications in a manner not recommended by a physician or manufacturer) or alcohol addiction.\n* Patients who have taken medications affecting the central nervous system within the past six months (e.g., central nervous system stimulants, sympathomimetic agents).\n* Patients with psychological abnormalities (e.g., schizophrenia, severe depression, bipolar disorder).\n* Individuals with severe head surface injuries or potential allergies to materials in contact with the head (such as conductive gels, head silicone membranes)",{"count":570,"type":21},20,[24],"Focused ultrasound (FUS) has been shown to differentially lesion or modulate (excite and inhibit) brain circuit and neural activity across a broad range of acoustic stimulus parameters (intensity, duty cycle, pulse repetition frequency and pulse duration) for decades. From our previous study, FUS sonication may suppress the number of epileptic signal bursts observed in EEG recordings after the induction of acute epilepsy. The presence of the suppressive effect was found in terms of the number of epileptic EEG spikes from the analysis of the unfiltered and theta-band EEG activity, and further discontinue the seizure attacks. EEG activity has also been consistently reported to have a positive correlation with the level of epilepsy, and FUS-mediated reduction of epileptic EEG activity was most notably observed, no matter lesioning or modulating effects. The aims of this study are to demonstrate the safety and efficacy of FUS technology in epilepsy patients and to estimate the optimal parameters of focused ultrasound exposure that will be used in the case of epilepsy.",[574,575,576,577,578],"Focused Ultrasound","MR-guided FUS","Drug Refractory Epilepsy","Drug Resistant Epilepsy","Medication Resistant Epilepsy","2025-09-02",{"date":581,"type":41},"2025-09-09",{"date":583,"type":41},"2024-01-01",{"date":126,"type":21},{"name":47,"class":48},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":187,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":592,"targetDuration":4,"studyType":22,"phases":594,"briefSummary":595,"conditions":596,"keywords":598,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":609,"locationsCount":4},"100604276","digital-health-platform-blood-pressure-management-study-100604276","NCT07147413","Digital Health Platform Blood Pressure Management Study","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1. Aged 18 to 75 years at the time of enrollment\n2. Able and willing to provide informed consent\n3. Able to operate a mobile phone and interact with the digital platform\n4. Willing to participate in home blood pressure monitoring\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Systolic BP consistently \\\u003C120 mmHg and diastolic BP \\\u003C70 mmHg, based on baseline home monitoring (considered low BP not targeted in this study)\n2. Pregnant or planning to become pregnant during the study period\n3. Unable to operate a smartphone or digital device independently\n4. Cognitive impairment or language barrier that prevents understanding of study procedures or informed consent\n5. Severe comorbidities that may interfere with study participation or outcomes (e.g., advanced heart failure, end-stage renal disease)\n6. Current participation in another interventional clinical study that could conflict with this protocol\n7. Unwillingness to follow home blood pressure monitoring protocol or adhere to follow-up schedule",{"count":593,"type":21},10000,[24],"This pilot study evaluated the effectiveness of an AI health education assistant compared to case manager support in hypertension management. Key outcomes included changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP), compliance with health behaviors, 722 goal achievement (monitoring, measurements, lifestyle improvements), and Technology Acceptance Model (TAM) metrics, including perceived usefulness (PU), perceived ease of use (PEU), and behavioral intention (BI). This study aims to examine whether the AI assistant group will achieve greater reductions in systolic and diastolic blood pressure compared to the case manager group. Additionally, it will evaluate whether the AI assistant group will demonstrate higher engagement in 722 goals and greater perceived ease of use. The results of this study are expected to provide further evidence supporting the potential of AI-driven interventions.",[597],"Hypertension Prevention and Management",[599,600,601,602],"Hypertension","Blood pressure","Prevention","Management","2025-08-28",{"date":605,"type":41},"2025-08-29",{"date":607,"type":21},"2025-09-01",{"date":126,"type":21},{"name":47,"class":48},{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":618,"enrollmentInfo":619,"targetDuration":4,"studyType":22,"phases":621,"briefSummary":623,"conditions":624,"keywords":628,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":636,"locationsCount":49},"100604606","phase-3-topical-versus-injection-prp-for-olfactory-dysfunction-100604606","NCT07151703","Topical Versus Injection PRP for Olfactory Dysfunction","Carrier-Assisted Topical Application Versus Intranasal Injection of Autologous Platelet-Rich Plasma for Olfactory Dysfunction: A Randomized Controlled Trial","TOP-IN","Inclusion Criteria:\n\n* Aged between 18 and 80 years, regardless of sex\n* Subjective complaint of olfactory dysfunction with confirmed hyposmia or anosmia based on standardized olfactory testing\n* History of at least 3 months of prior olfactory training but with persistent olfactory complaints\n\nExclusion Criteria:\n\n* Congenital anosmia\n* Diagnosed neurological or structural brain abnormalities (e.g., brain tumor, major head trauma, stroke) with low likelihood of olfactory recovery\n* Inability or unwillingness to comply with study procedures or follow-up assessments","80 Years",{"count":620,"type":21},60,[622],"PHASE3","The goal of this clinical trial is to determine whether two different delivery methods of autologous platelet-rich plasma (PRP) can improve olfactory function in adults with persistent olfactory dysfunction lasting more than three months. The main questions it aims to answer are:\n\n1. Does carrier-assisted topical application of PRP lead to comparable or better improvement in smell function than intranasal injection of PRP?\n2. Which method provides greater patient comfort and fewer adverse effects?\n\nResearchers will compare carrier-assisted topical PRP application to intranasal PRP injection to see if one approach is more effective in restoring olfactory function.\n\nParticipants will:\n\n1. Receive a single PRP treatment delivered either by injection or via a PRP-soaked carrier placed into the olfactory cleft.\n2. Continue daily olfactory training for three months following the intervention.\n3. Undergo smell testing (Sniffin' Sticks) before and after treatment and complete quality-of-life questionnaires.",[625,626,627],"Olfactory Dysfunction","Anosmia","Hyposmia",[626,627,629,630,245],"Platelet-Rich Plasma (PRP)","Intranasal Injection","2025-08-25",{"date":539,"type":41},{"date":634,"type":21},"2025-10-01",{"date":45,"type":21},{"name":47,"class":48},{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":643,"targetDuration":4,"studyType":22,"phases":644,"briefSummary":646,"conditions":647,"keywords":651,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":654,"lastUpdatePostDateStruct":655,"startDateStruct":657,"completionDateStruct":658,"leadSponsor":659,"locationsCount":49},"100598558","phase-4-the-role-of-glucagon-like-peptide-1-receptor-agonists-in-coronary-artery-diseases-and-their-potential-mechanisms-100598558","NCT07073053","The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms","Inclusion Criteria:\n\n1. adults (\\>=20 years old),\n2. Type 2 Diabetes with coronary arterial disease underwent angioplasty within 3 months with SGLT2 inhibitors -\n\nExclusion Criteria:\n\n1. age\\\u003C20 years old,\n2. pregnant women,\n3. eGFR\\\u003C30 ml\u002Fmin\u002F1.73m2,\n4. received GLP-1 agonist in the recent 3 months -",{"count":620,"type":21},[645],"PHASE4","The investigators plan to enroll 60 patients from the outpatient clinics or inpatient wards of the Metabolism and Cardiology departments who, within the past three months, have undergone coronary angiography for the treatment of coronary artery disease, are currently using sodium-glucose cotransporter-2 (SGLT-2) inhibitors for glycemic control, and have not received glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy for more than three months. A randomized controlled clinical trial will be conducted, with 20 participants randomly assigned to receive semaglutide (a GLP-1 RA) at 1 mg once weekly for 6 months, another 20 participants to receive semaglutide at 0.5 mg once weekly for 6 months, and the control group (20 participants) to continue with standard treatment for 6 months. The effects after 6 months will be evaluated in terms of endothelial function, glycemic control indicators including glycemic variability assessed via continuous glucose monitoring (CGM), oxidative stress markers, and the incidence of symptomatic hypoglycemia.\n\nAccording to the treatment guidelines for type 2 diabetes, either GLP-1 receptor agonists or SGLT-2 inhibitors should be prioritized in patients with type 2 diabetes and coronary artery disease. Therefore, the medication choices in both the intervention and control groups in this study align with current treatment guidelines.",[648,649,650],"Glucagon-Like Peptide-1 Receptor Agonists","Type 2 Diabetes","Coronary Arterial Disease (CAD)",[648,652,653],"type 2 diabetes","coronary arterial disease","2025-07-09",{"date":656,"type":41},"2025-07-18",{"date":634,"type":21},{"date":80,"type":21},{"name":47,"class":48},{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":665,"acronym":666,"eligibilityCriteria":667,"healthyVolunteers":187,"sex":135,"minAge":18,"maxAge":4,"enrollmentInfo":668,"targetDuration":4,"studyType":22,"phases":670,"briefSummary":671,"conditions":672,"keywords":674,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":49},"100594319","applying-breast-mask-containing-cabbage-leaves-extract-to-relieve-breast-discomfort-in-breastfeeding-women-100594319","NCT07017894","Applying Breast Mask Containing Cabbage Leaves Extract to Relieve Breast Discomfort in Breastfeeding Women","Applying Breast Mask Containing Cabbage Leaves Extract to Relieve Breast Discomfort in Breastfeeding Women：A Double-blind Randomized Controlled Trial","BMCCLE","Inclusion Criteria:\n\n* Over 18 years old.\n* Breastfeeding.\n* Physiological breast swelling, breast heaviness, lumps, milk plugging, breast pain after childbirth.\n* Able to read and understand Chinese.\n\nExclusion Criteria:\n\n* Stillbirth\n* Allergy to cabbage or sulfa.\n* lactation inhibitors agents used.\n* Fever symptoms (\\> 38 degrees Celsius), including: wound infection, upper respiratory tract infection, urinary tract infection.\n* Breast symptoms, including: nipple cracks, skin damage, breast abscesses, mastitis, Malignant tumors.\n* Postpartum complications, including: postpartum hemorrhage, amniotic fluid embolism or other diseases requiring close care.",{"count":669,"type":21},154,[24],"In this article, women were randomly assigned to the Breast Mask Containing Cabbage Leaves Extract group and Breast Mask without Cabbage Leaves Extract group, and the breast engorgement, pain, hardness, before and after each treatment were measured. At the end of the study breast mask user experience and continued breastfeeding were measured.",[673],"Breast Engorgement",[675,676,677],"breast engorgement","pain","hardness","2025-06-04",{"date":680,"type":41},"2025-06-12",{"date":682,"type":21},"2025-06-01",{"date":684,"type":21},"2026-04-13",{"name":47,"class":48},""]